Huth J F, Gupta R K, Eilber F R, Morton D L
Cancer. 1984 Mar 15;53(6):1306-10. doi: 10.1002/1097-0142(19840315)53:6<1306::aid-cncr2820530614>3.0.co;2-g.
Tumor-associated antigens (TAA) excreted into the urine of sarcoma patients can be detected by the complement-fixation assay. The authors prospectively measured TAA levels in the urine of 50 sarcoma patients postoperatively to determine whether reappearance of antigen in the urine would be predictive of disease recurrence. Twenty-five patients developed recurrence of their disease in the postoperative period, and 24 (96%) had reappearance of antigen in the urine 10.1 +/- 9.2 months prior to clinical evidence of recurrence. Of the 25 patients who remained disease free (mean follow-up, 48 months), 23 of 25 (92%) were urinary-antigen negative at last follow-up, although 8 patients had transient elevations of urinary TAA early in the postoperative period. Results indicate that postoperative measurement of urinary TAA in sarcoma patients permits selection of a subset of individuals at high risk for the development of recurrence. This knowledge can be of assistance in the postoperative management of these patients.
通过补体结合试验可检测出肉瘤患者尿液中排出的肿瘤相关抗原（TAA）。作者前瞻性地测定了50例肉瘤患者术后尿液中的TAA水平，以确定尿液中抗原的再次出现是否可预测疾病复发。25例患者在术后出现疾病复发，其中24例（96%）在临床出现复发证据前10.1±9.2个月尿液中出现了抗原再次出现。在25例无疾病复发的患者中（平均随访48个月），25例中有23例（92%）在最后一次随访时尿液抗原呈阴性，尽管有8例患者在术后早期尿液TAA出现短暂升高。结果表明，对肉瘤患者术后尿液TAA进行检测，有助于筛选出复发风险较高的一部分患者。这一认识有助于这些患者的术后管理。
